Anti-PD-1 therapy provides high response rates in Hodgkin lymphoma (HL) patients who have relapsed or are refractory (R/R) to autologous stem cell transplantation (ASCT) and brentuximab vedotin (BV), but median progression free survival (PFS) is only one year. The efficacy of treatment following anti-PD-1 is not well known. We retrospectively investigated the efficacy of salvage therapies for unsatisfactory response to anti-PD-1 therapy, assessed by PET-CT according to the Lugano criteria, in 30 R/R HL patients. Patients were highly pretreated before anti-PD-1 (70%
the median PFS following the initiation of CT was 11 months (95% CI 6.3-not reached) and the median of overall survival was not reached. These observations in highly pretreated HL patients suggest that anti-PD-1 therapy might re-sensitize tumor cells to CT.
| I N T R O D U C T I O N
Although the vast majority of patients with early-stage 1 or advancedstage 2, 3 classical Hodgkin Lymphoma (HL) are cured with the first line treatment, a subset of patients relapses and requires salvage therapy followed by autologous stem cell transplant (ASCT). 4, 5 Patients who relapse after ASCT or are not eligible for high-dose therapy are usually treated with chemotherapy (CT) or brentuximab vedotin (BV), 6 ,7 an
anti-CD30 antibody-drug conjugate. For HL patients who relapse or are refractory (R/R) to ASCT and BV, programmed death-1 (PD-1) directed therapy offers a new therapeutic option with an impressive efficacy and a favorable side-effect profile. [8] [9] [10] [11] However, among the two thirds of patients who reached a response to PD-1 blockers (nivolumab 8, 10 or pembrolizumab 9, 11 ) only 12-30% obtained a complete response (CR). In addition, a substantial proportion of patients will ultimately relapse, with a median progression-free survival (PFS) of 12 months, and 10 months in pivotal studies with nivolumab and pembrolizumab, respectively. 10, 12 Similar results have been observed in daily practice. 13 In this context, the optimal treatment for patients who failed after anti-PD-1 therapy is an issue. To better assess their outcome, we retrospectively analyzed the characteristics and outcome of patients from 14 LYSA (The Lymphoma Study Association) centers who lost response to anti-PD-1 therapy and received additional CT.
| M E T H O D S

| Patients
The initial diagnosis of classical HL was established from biopsies in accordance with the 2008 World Health Organization classification. 14 We retrospectively analyzed 30 R/R classical HL patients from 14
LYSA centers who received anti-PD-1 therapy as part of a clinical trial response and outcome under this treatment. After the review, we identified two groups of patients for this study based on the strategy used by each treating physician: 19 patients (63%) for whom anti-PD-1 therapy was stopped with the introduction of a new treatment line (Group 1 or sequential strategy) and 11 patients (37%) for whom a combination of CT with anti-PD-1 therapy was initiated (Group 2 or concomitant strategy). Though we studied 30 patients, we focused mainly on the 24 patients who were considered in failure (SD or PD) after anti-PD-1 blockers. We also reported the results of the remaining 6 patients with partial response (PR) for whom a similar strategy was applied to improve anti-PD-1 response.
The study was approved by ethic committee of Lyon.
| Study design and endpoints
The primary objective of this retrospective study was to evaluate the improvement in response from the end of anti-PD-1 monotherapy to the first evaluation after introduction of CT alone (Group 1) or combined with anti-PD-1 (Group 2). Patient evaluation was timed by treating physicians according to the policy of each center, and all patients were evaluated after a median of 10 weeks (min 7 weeks, max 12 weeks) with PET/CT using Lugano criteria. 15 
| Histopathology and immunohistochemistry
Tumor samples were obtained from four HL patients during anti-PD-1 monotherapy. These samples were fixed in 10% buffered formalin, 
| Statistical considerations
OS was defined as the time from the date of the first treatment after anti-PD-1 monotherapy to the date of death from any cause (event) or last follow-up (censored data). PFS was defined as the time from the first treatment after anti-PD-1 monotherapy to progression or death (event) or last follow-up/change of treatment (censored data). All survival rates were estimated by the Kaplan-Meier method with 95% confidence intervals (CI). Median follow-up was calculated with the Kaplan-Meier reverse method. 16 All statistical analyses were performed using STATA 12.0 software. (Table 1 ). All patients had multi-refractory disease: the median number of lines of CT was six (2-14); 70% of patients had previously received ASCT, and 93% had been treated with BV. Four patients (13%) received allo-SCT before starting anti-PD-1 therapy (Table 1) .
| Anti-PD-1 monotherapy
The The median PFS under anti-PD-1 therapy was 7.5 months (IC95%, 5.7-11.6).
| Treatment after anti-PD-1 monotherapy
In Group 1 (sequential strategy) (n 5 19), when anti-PD-1 was switched to CT, 16 patients had PD (85%), one patient had SD (5%) and two patients had PR (10%). After discontinuation of anti-PD-1 therapy, patients were treated with vinblastine (n 5 3), gemcitabine (n 5 2) or bendamustine alone (n 5 3) or in combination with BV (n 5 4), GVD Table S1 ). In this group, patients received a median of 6 cycles of CT (range: 2-14). In Group 2 (concomitant strategy) (n 5 11), the response status was PD in seven patients (63%) and PR in four patients (36%) before the treatment switch. Patients received vinblastine (n 5 7), gemcitabine (n 5 2) and BV (n 5 2) in combination with anti-PD-1 therapy (Supporting Information Table S1 ). In this group, patients received a median of 7 CT cycles (range: 3-10).
Overall, the CT regimen included single agent CT (n 5 20, 67%), BV alone (n 5 2) or CT regimens (GVD, n 5 1; escalated BEACOPP, n 5 1; bendamustine-BV, n 5 4, ICE, n 5 1; DHAP, n 5 1). Vinca alkaloids alone (vinblastine, vinorelbine) were the most frequently used class of CT (n 5 11; 37%).
In this study, 15 patients (50%) were re-exposed to the same CT agent that they had received previous to the anti-PD-1 therapy. Among them, 6 initially had refractory disease, 6 had CR and 3 had PR after their first exposure to CT. 6/11 (55%) patients in Group 2 and 9/19 (47%) in Group 1, were re-exposed to a previously used CT regimen with a median time gap of 22 months (range, 0.8-38.8), and 23 months (range, 12-68), respectively ( Table 2) . Table 2 . In Group 1, there were 7 CR (41%), 3 PR (18%), 5 PD (21%) and 2 not evaluated (12%);
in Group 2, there were 4 CR (57%), 2 PR (29%) and 1 SD (14%) Page: 4
( Figure 1 and Table 3 ). Notably, among the 10 patients in Group 1 (n 5 3) and 2 (n 5 7) treated with vinblastine, 7 had CR (54%), 3 PR (23%), 1 SD (8%) and 2 progressed (15%). In the subset of patients re-exposed to the same CT regimen, the overall response rate (ORR) was 80% (12/15) with 8 patients reaching CR and 4 PR. Interestingly, among the 6/15 patients refractory to the prior chemotherapy, the ORR to the second exposure to the same chemotherapy was 4/6 (66%) with three patients in CR and one of them in PR. Our results are in line with a recent study on lung cancer in which 16% patients exhibited a response after a sequence anti-PD-1 (second line) followed by CT (third line), whereas a line of CT without prior exposure to anti-PD-1 did not result in an objective response. 23 We observed a better improvement of response in Group 2 (ORR, 86%) compared to Group 1 (ORR, 59%). However, patients were younger (32 y versus 44 y) in Group 2 and had progressive disease less frequently after anti-PD-1 therapy (64% versus 89%). On the basis of this series it is difficult to conclude which is the best strategy: stopping anti-PD-1 therapy or combining it with CT.
In four patients with available biopsy during anti-PD-1 therapy, we CR, but this combination was performed for R/R HL patients after frontline therapy without pretreatment with BV or ASCT. 25 Consolidation allo-SCT was performed in six patients with only one case of severe cutaneous GVHD. This strategy was previously described as feasible with good disease control but with increased early immune toxicities. 25, 26 In a study by Merryman et al., grade 3 and 4
GVHD was observed in 23% of patients in the first year with four deaths from treatment-related complications. 27 Whether receiving CT before allo-SCT could modulate the immune system and reduce immune side effects should be prospectively studied in a larger cohort of patients with specific immune monitoring.
Our study had several limitations. First, we only studied a subset of patients who had a sub-optimal response to anti-PD-1 therapy, and who are not representative of a global cohort of R/R HL patients treated with anti-PD-1 therapy. In this setting, it could be interesting to compare the outcome for progressive patients who continue anti-PD-1 24 and progressive patients for whom new treatment is introduced, as was done for our patients. For the latter option, the best timing to re-introduce CT should also be investigated. Secondly, Lyric criteria 17 were not assessed prospectively in this study because these criteria were published after the treatment of the patients in our series. Thirdly, the type of CT used was heterogeneous, depending of the previous treatment received by the patient and the choice of the physician.
In conclusion, our study showed that 67% of patients experienced new objective response after failure to respond to anti-PD-1 monotherapy, including 46% CR with CT alone (59%) or in combination with anti-PD-1 therapy (86%). These results support the idea that anti-PD-1 therapy re-sensitizes patient response to CT and could give certain patients the option of receiving allo-SCT. Prospective clinical trials on larger cohorts are needed to confirm the synergistic effect of CT with anti-PD-1 therapy and determine the CT that provides the best results in combination with these checkpoint inhibitors.
